Literature DB >> 10799521

Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation.

G Mbalaviele1, Y Abu-Amer, A Meng, R Jaiswal, S Beck, M F Pittenger, M A Thiede, D R Marshak.   

Abstract

The nuclear receptor and transcription factor, peroxisome proliferator-activated receptor-gamma (PPAR-gamma), regulates the activity of other transcription factors in the adipogenic differentiation and inflammatory response pathways. We examined the possible function of the PPAR-gamma pathway in osteoclast (Ocl) formation from CD34(+) hematopoietic stem cells (CD34(+) HSCs), using a co-culture system comprised of human mesenchymal stem cells (hMSCs) and CD34(+) HSCs, both derived from bone marrow. Ocl formation in this co-culture system is enhanced by the addition of exogenous osteoprotegerin ligand (OPGL), an essential Ocl differentiation factor, and macrophage-colony stimulating factor (M-CSF). The data indicate that soluble OPGL (sOPGL) and M-CSF stimulate Ocl formation in the co-cultures up to 4-fold compared with CD34(+) HSCs alone treated with sOPGL and M-CSF. CD34(+) HSCs, but not hMSCs, express PPAR-gamma, and 15-deoxy-Delta(12, 14)-prostaglandin-J2 (15d-PG-J2), a PPAR-gamma agonist, completely blocked the effects of sOPGL and M-CSF on Ocl formation and activity. The inhibitory effect of 15d-PG-J2 is specific to the Ocl lineage in both human and mouse models of osteoclastogenesis. Accordingly, parallel experiments demonstrate that sOPGL activates the NF-kappaB pathway within mouse Ocl progenitors, and this effect was abolished by 15d-PG-J2. These data establish a link between PPAR-gamma and OPGL signaling within Ocl progenitors, and support a role for PPAR-gamma pathway in the modulation of osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799521     DOI: 10.1074/jbc.275.19.14388

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.

Authors:  A C Bendixen; N K Shevde; K M Dienger; T M Willson; C D Funk; J W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

2.  Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism.

Authors:  Aleksandra Mieczkowska; Michel F Baslé; Daniel Chappard; Guillaume Mabilleau
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

3.  Cellular and molecular effects of thiazolidinediones on bone cells: a review.

Authors:  Guillaume Mabilleau; Daniel Chappard; Michel F Baslé
Journal:  Int J Biochem Mol Biol       Date:  2011-06-20

4.  Lentivirus transduction of human osteoclast precursor cells and differentiation into functional osteoclasts.

Authors:  Margaret L Ramnaraine; Wendy E Mathews; Denis R Clohisy
Journal:  Bone       Date:  2011-10-01       Impact factor: 4.398

5.  Thiazolidinediones and bone.

Authors:  Alberto Falchetti; Laura Masi; Maria Luisa Brandia
Journal:  Clin Cases Miner Bone Metab       Date:  2007-05

Review 6.  Risk of fractures with glitazones: a critical review of the evidence to date.

Authors:  Michael Bodmer; Christian Meier; Marius E Kraenzlin; Christoph R Meier
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study.

Authors:  J Tamaki; M Iki; A Morita; Y Ikeda; Y Sato; E Kajita; S Kagamimori; Y Kagawa; H Yoneshima
Journal:  Osteoporos Int       Date:  2009-05-30       Impact factor: 4.507

8.  A cohort study of thiazolidinediones and fractures in older adults with diabetes.

Authors:  Daniel H Solomon; Suzanne M Cadarette; Niteesh K Choudhry; Claire Canning; Raisa Levin; Til Stürmer
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

9.  Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone.

Authors:  Unni Syversen; Astrid K Stunes; Björn I Gustafsson; Karl J Obrant; Lars Nordsletten; Rolf Berge; Liv Thommesen; Janne E Reseland
Journal:  BMC Endocr Disord       Date:  2009-03-30       Impact factor: 2.763

10.  Transcripts of unknown function in multiple-signaling pathways involved in human stem cell differentiation.

Authors:  Kunio Kikuchi; Makiha Fukuda; Tomoya Ito; Mitsuko Inoue; Takahide Yokoi; Suenori Chiku; Toutai Mitsuyama; Kiyoshi Asai; Tetsuro Hirose; Yasunori Aizawa
Journal:  Nucleic Acids Res       Date:  2009-06-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.